Outcomes after dose escalation of infliximab in Japanese patients with Crohn's disease

被引：0
|
作者：
Sako, M. [1 ]
Kawaguchi, T. [1 ]
Hirayama, A. [1 ]
Fukushi, G. [1 ]
Hayama, K. [1 ]
Fujiwara, T. [1 ]
Yoshimura, N. [1 ]
Takazoe, M. [1 ]
机构：
[1] Social Insurance Cent Hosp, Ctr Inflammatory Bowel Dis, Tokyo, Japan
来源：
JOURNAL OF CROHNS & COLITIS | 2014年 / 8卷
关键词：
D O I：
10.1016/S1873-9946(14)60517-1
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P397
引用
收藏
页码：S231 / S231
页数：1
相关论文
共 50 条
  • [41] INFLIXIMAB DE-ESCALATION IN PATIENTS WITH CROHN'S DISEASE IN CLINICAL REMISSION IS SAFE AND WELL TOLERATED
    Allegretti, Jessica R.
    McClure, Emma L.
    Marcus, Jenna
    Norton, Beth Ann
    Hamilton, Matthew
    Winter, Rachel
    De Silva, Punyanganie
    Friedman, Sonia
    Korzenik, Joshua R.
    GASTROENTEROLOGY, 2020, 158 (06) : S461 - S461
  • [42] Rate of Ustekinumab Dose Escalation in Patients With Crohn's Disease Who Had a History of Anti-TNF Dose Escalation
    Sun, Kelly
    Manski, Scott
    Crawford, Albert
    Shivashankar, Raina
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (12S): : S5 - S5
  • [43] Ustekinumab Dose Escalation Is Effective in Treatment of Crohn's Disease
    Cohen, Erica
    Ha, Christina
    Syal, Gaurav
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S384 - S385
  • [44] Ustekinumab use in Crohn's disease: effectiveness of dose escalation
    Greenup, A.
    Rosenfeld, G.
    Bressler, B.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S400 - S400
  • [45] Predictors of adalimumab dose escalation in patients with crohn's disease at a tertiary referral center
    Cohen, Russell D.
    Lewis, Jeffrey R.
    Turner, Hannah
    Harrell, Laura E.
    Hanauer, Stephen B.
    Rubin, David T.
    INFLAMMATORY BOWEL DISEASES, 2012, 18 (01) : 10 - 16
  • [46] Effect of Ustekinumab Dose Escalation on Recapturing Clinical Response in Patients With Crohn's Disease
    Bundschuh, Mark
    McDonough, Gregory
    Kumar, Priyanka
    Kozuch, Patricia
    Shivashankar, Raina
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S452 - S452
  • [47] Better off NaiVE: Predictors of Adalimumab Dose Escalation in Patients With Crohn's Disease
    Moncrief, Karli
    Steinhart, A. Hillary
    Croitoru, Ken
    Newman, Alvin
    Nguyen, Geoffrey C.
    Xu, Wei
    Silverberg, Mark S.
    GASTROENTEROLOGY, 2012, 142 (05) : S359 - S359
  • [48] SUBCUTANEOUS INFLIXIMAB: MIDTERM TREATMENT OUTCOMES IN PATIENTS WITH REFRACTORY CROHN'S DISEASE AFTER MULTIPLE TREATMENT FAILURES
    Cerna, Karin
    Lukas, Milan
    GASTROENTEROLOGY, 2023, 164 (06) : S1127 - S1128
  • [49] SUBCUTANEOUS INFLIXIMAB IN REFRACTORY CROHN'S DISEASE PATIENTS AFTER THE MULTIPLE TREATMENT FAILURES - SHORT TREATMENT OUTCOMES
    Lukas, Milan
    Jirsa, Jakub
    Lukas, Martin
    Kolar, Martin
    Machkova, Nadezda
    Duricova, Dana
    Hruba, Veronika
    Kastylova, Kristyna
    Cerna, Karin
    GASTROENTEROLOGY, 2023, 164 (04) : S97 - S97
  • [50] Predictors and Timing of Adalimumab (ADA) Dose Escalation in Patients with Crohn's Disease (CD)
    Cohen, Russell D.
    Lewis, Jeffrey R.
    Turner, Hannah
    Hanauer, Stephen B.
    Rubin, David T.
    GASTROENTEROLOGY, 2009, 136 (05) : A652 - A652
12345